# KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Source: https://onco.cc/trials/nct05294172/  
OnCo record `nct05294172` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing KL-A167 in nasopharyngeal carcinoma, active and no longer recruiting.

## Summary

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma is a phase 3 interventional study registered as NCT05294172, led by Sichuan Kelun-Biotech Biopharmaceutical, and active but no longer recruiting on the registry. Official title: KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomised, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial. Planned enrolment is 295 participants (actual). The study started in 2022-06-07 and primary completion is expected in 2027-12. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Tags: ctgov-ingest
- Registry id: NCT05294172
- Phase: 3
- Setting: KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Trial
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical
- Enrolled: 295

## Sources

- ClinicalTrials.gov NCT05294172: https://clinicaltrials.gov/study/NCT05294172

## Connected records

- cancers: [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Recurrent and metastatic nasopharyngeal carcinoma](https://onco.cc/cancers/recurrent-metastatic-nasopharyngeal-carcinoma/)
- drugs: [KL-A167](https://onco.cc/drugs/kl-a167/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct05294172.json